Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.
Recent comments
4 days 15 hours ago
1 week 5 days ago
1 week 5 days ago
22 weeks 5 days ago
26 weeks 6 days ago
28 weeks 3 days ago
28 weeks 4 days ago
40 weeks 6 days ago
46 weeks 4 days ago
1 year 5 weeks ago